首页|N-glycan profiles of acute myocardial infarction patients reveal potential biomarkers for diagnosis, severity assessment, and treatment monitoring

N-glycan profiles of acute myocardial infarction patients reveal potential biomarkers for diagnosis, severity assessment, and treatment monitoring

扫码查看
Acute myocardial infarction (AMI) is a leading cause of mortality and morbidity worldwide. Diagnostic challenges remain in this highly time-sensitive condition. Using capillary electrophoresis-laser-induced fluorescence, we analyzed the blood plasma N-glycan profile in a cohort study comprising 103 patients with AMI and 69 controls. Subsequently, the data generated was subjected to classification modeling to identify potential AMI biomarkers. An area under the Receiving Operating Characteristic curve (AUC(ROC)) of 0.81 was obtained when discriminating AMI versus non-MI patients. We postulate that the glycan profile involves a switch from a pro- to an anti-inflammatory state in the AMI pathophysiology. This was supported by significantly decreased levels in galactosylation, alongside increased levels in sialylation, afucosylation, and GlcNAc bisection levels in the blood plasma of AMI patients. By substantiating the glycomics analysis with immunoglobulin G (IgG) protein measurements, robustness of the glycan-based classifiers was demonstrated. Changes in AMI-related IgG activities were also confirmed to be associated with alterations at the glycosylation level. Additionally, a glycan-biomarker panel (GBP) derived from glycan features and current clinical biomarkers performed remarkably (AUC(ROC) = 0.90, sensitivity = 0.579 at 5 percent false positive rate) when discriminating between patients with ST-segment elevation MI (n = 84) and non-ST-segment elevation MI (n = 19). Moreover, by applying the model trained using glycomics information, AMI and controls can still be discriminated at one and six months after baseline. Thus, glycomics biomarkers could potentially serve as a valuable complementary test to current diagnostic biomarkers. Additional research on their utility and associated biomechanisms via a large-scale study is recommended.

GlycomicsGlycanCoronary heart diseaseBiomarkerAcute myocardial infarctionCORONARY-HEART-DISEASEBLOOD-CELL COUNTATHEROSCLEROSIS RISKIMMUNOGLOBULIN-GSENSITIVE ASSAYASSOCIATIONMORTALITYIGGAGEAMERICAN

Lim, Si Ying、Hendra, Christopher、Yeo, Xin Hao、Tan, Xin Yi、Ng, Bao Hui、Laserna, Anna Karen Carrasco、Tan, Sock Hwee、Chan, Mark Yan Yee、Khan, Shaheer H.、Chen, Shiaw-Min、Li, Sam Fong Yau

展开 >

NUS Grad Sch Integrat Sci & Engn NGS,Natl Univ Singapore

Dept Chem,Natl Univ Singapore

Yong Loo Lin Sch Med,Natl Univ Singapore

Thermo Fisher Sci

展开 >

2022

Glycobiology.

Glycobiology.

ISSN:0959-6658
年,卷(期):2022.32(6)
  • 2
  • 48